Author(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical Background Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy with a high rate of durable complete responses and a manageable safety profile in adult patients (pts) with R/R DLBCL. Aims To report long-term follow up...
Pro zobrazení tohoto obsahu je třeba být přihlášen.